Palatin Technologies Stock Price

0.0029 (0.45%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Palatin Technologies Inc New PTN AMEX Common Stock
  Price Change Change Percent Stock Price Last Traded
0.0029 0.45% 0.6532 19:56:55
Open Price Low Price High Price Close Price Prev Close
0.6475 0.6301 0.6578 0.657 0.6503
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
3,145 1,051,051 $ 0.6477793 $ 680,849 8,059,147 0.375 - 1.30
Last Trade Time Type Quantity Stock Price Currency
20:00:00 1,434 $ 0.657 USD

Palatin Technologies Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 150.17M 229.90M 226.66M $ 117.99k $ - -0.10 -10.70
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Palatin Technologies News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical PTN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.7150.72080.62020.669951,888,311-0.0618-8.64%
1 Month0.73560.8288990.62020.73060032,574,665-0.0824-11.2%
3 Months0.821.300.60050.94040766,253,873-0.1668-20.34%
6 Months0.46771.300.3750.81859194,709,0930.185539.66%
1 Year0.421.300.3750.73613483,302,8820.233255.52%
3 Years1.292.210.3310.87876642,183,768-0.6368-49.36%
5 Years0.482.210.28510.78812651,966,8360.173236.08%

Palatin Technologies Description

Palatin Technologies Inc is a part of the healthcare sector. The company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its main product in clinical development is bremelanotide, which treats hypoactive sexual desire disorder, which is a type of female sexual dysfunction.

Your Recent History
Palatin Te..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.